

REFERENCIAS

- 1.- Semelka, RC, Helmberger,TK. Contrast agents for MR imaging of the liver. Radiology 2001; 218:27-38.
- 2.- Hahn PF, Saini S. Liver-specific MR imaging contrast agents. Radiol Clin N Am 1998; 36: 287-297.
- 3.- Chung JJ, Kim MJ, Kim KW. J. Mangafodipir Trisodium-enhanced MRI for the detection and characterization of focal hepatic lesions: Is delayed imaging useful?. Magn Reson Imaging 2006; 23:706-711.
- 4.- Murakami T, Baron RL, Peterson MS, et al. Hepatocellular carcinoma : MR imaging with mangafodipir trisodium (Mn-DPDP). Radiology 1996; 200: 69-77.
- 5.- Coffin CM, Diche T, Mahfouz E, et al. Benign and malignant hepatocellular tumors : evaluation of tumoral enhancement after mangafodipir trisodium injection on MR imaging. Eur Radiol 1999; 9:444-449.
- 6.- Federle M, Chezmar J, Rubin D, et al. Efficacy and safety of mangafodipir trisodium (Mn-DPDP) injection for hepatic MRI in adults : results of the US multicenter phase III clinical trials. Efficacy of early imaging. J Magn Reson Imaging 2000; 12: 689-701.
- 7.- Braga HJ, Choti MA, Lee VS et al. Liver lesions : Manganese-enhanced MR and dual-phase helical CT for preoperative detection and characterization- Comparison with receiver operating characteristic analysis. Radiology 2002; 223: 525-531.
- 8.- Oudkerk M, Torres CG, Song B et al. Characterization of liver lesions with mangafodipir trisodium-enhanced MR imaging: multicenter study comparing MR and dual-phase spiral CT. Radiology 2002; 223-517-524.
- 9.- Kim KW, Kim AY, Kim TK, et al. Small (≤ 2 cm) hepatic lesions in colorectal cancer patients: Detection and characterization on mangafodipir trisodium-enhanced MRI. AJR 2004; 182:1233-1240.
- 10.- Sahani DV, Kalva SP, Fischman AJ et al. Detection of liver metastases from adenocarcinoma of the colon and pancreas: Comparison of mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET. AJR 2005; 185: 239-246.

- 11.- Youk JH, Lee JM, Kim CS. MRI for detection of hepatocellular carcinoma: Comparison of mangafodipir trisodium and gadopentetate dimeglumine contrast agents. *AJR* 2004; 183:1049-1054.
- 12.- Kim HJ, Kim KW, Byun JH, et al. Comparison of mangafodipir trisodium and ferucarbotran-enhanced MRI for detection and characterization of hepatic metastases in colorectal cancer patients. *AJR* 2006; 186:1059-1066.
- 13.- Scharitzer M, Shima W, Schober E, et al. Characterization of hepatocellular tumors. Value of mangafodipir-enhanced magnetic resonance imaging. *J Comput Assist Tomogr* 2005; 29: 181-190.
- 14.- Regge D, Campanella D, Anselmetti GC et al. Diagnostic accuracy of portal-phase CT and MRI with mangafodipir trisodium in detecting liver metastases from colorectal carcinoma. *Clin Radiol* 2006; 61: 338-347.
- 15.- Lee VS, Rofsky NM, Morgan GR et al. Volumetric mangafodipir trisodium-enhanced cholangiography to define intrahepatic biliary anatomy. *AJR* 2001;176: 906-908.
- 16.- Vitelas KM, El-Dieb A, Vaswani KK, et al. Using contrast-enhanced MR cholangiography with IV mangafodipir trisodium (Teslascan) to evaluate bileductleaks alter cholecystectomy: A prospective study of 11 patients. *AJR* 2002;179:409-416.
- 17.- Yeh BM, Breiman RS, Taouli B, et al. Biliary tract depiction in living potential liver donors: Comparison of conventional MR, mangafodipir trisodium-enhanced excretory MR, and multi-detector row CT cholangiography- Initial experience. *Radiology* 2004;230:645-651.
- 18.- Lee VS, Krinsky GA, Nazzaro CA, et al. Defining intrahepatic biliary anatomy in living liver trasplant donor candidates at mangafodipir trisodium-enhanced MR cholangiography versus convencional T2-weighted MR cholangiography. *Radiology* 2004;233:659-666.
- 19.- Hottat N, Winant C, Metens T, et al. MR cholangiography with manganese dipyridoxyl diphosphate in evaluation of biliary-enteric anastomoses : preliminary experience. *AJR* 2005;184:1556-1562.
- 20.- Fayad L, Kamel IR, Mitchell DG et al. Functional MR cholangiography: diagnosis of functional abnormalities of the gallbladder and billiary tree. *AJR* 2005;184:1563-1571.

- 21.- Sheppard D, Allan L, Martin P, et al . Contrast-enhanced magnetic resonance cholangiography using mangafodipir compared with standard T2W MRC sequences: A pictorial essay. *J Magn Reson Imaging* 2004;20:256-263.
- 22.- Aduna M, Larena JA, Martin D, et al. Bile Duct leaks after laparoscopic cholecystectomy: value of contrast-enhanced MRCP. *Abdom Imaging* 2005;30:480-487.
- 23.- Caudana R, Morana G, Pirovano GP et a. Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA)-Preliminary results of phase II clinical application. *Radiology* 1996;199:513-520.
- 24.-Clement O, Siauve N, Cuenod C,et al. Mechanism of action of liver contrast agents. Impact for clinical use. *J Comput Assist Tomogr*, 1999; 23(suppl 1) :S45-S52.
- 25.-Kuwatsuru R, Kadoya M, Ohtomo K et al. Clinical late phase II trial of Multihance (Gd-BOPTA) for the magnetic resonance imaging of liver tumors in Japan. *J Comput Assist Tomogr* 1999;23(suppl.1):S65-S74
- 26.- Hamm B, Kirchin M, Pirovano G et al. Clinical utility and safety of Multihance in magnetic resonance imaging of liver cancer : Results of multicenter studies in Europe and USA. *J Comput Assist Tomogr* 1999;23(suppl 1) : S53-S60.
- 27.- Grazioli L, Kirchin M, Pirovano G, et al. Multihance in the dynamic phase of contrast enhancement : a pictorial assessment. *J Comput Assist Tomogr* 1999 ; (suppl 1): S61-S64.
- 28.- Petersein J, Spinazzi A, Giovagnoni A, et al. Focal liver lesions : Evaluation of efficacy of gadobenate dimeglumine in MR imaging- A multicenter phase III clinica study. *Radiology* 2000;215:727-736
- 29.- Schima W, Petersein J, Hahn P, et al. Contrast-enhanced MR imaging of the liver : Comparison between Gd-BOPTA and mangafodipir. *JMRI* 1997;7:130-135.
- 30.- Del Frate C, Bazzocchi M, Morteale K et al. Detection of liver metastases: Comparison of gadobenate dimeglumine-enhanced and ferumoxides-enhanced MR imaging examinatioes. *Radiology* 2002;225:766-772
- 31.- Grazioli L, Morana G, Kirchin M et al. MRI of focal nodular hyperplasia (FNH) with gadobenate dimeglumine (Gd-BOPTA) and SPIO (ferumoxides): an intra-individual comparison. *JMRI* 2003;17:593-602.

- 32.- Grazioli L, Morana G, KirchinM, et al. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging. Prospective study. *Radiology* 2005;236:166-177.
- 33.- An SK, Lee JM, Suh KS et al. Gadobenate dimeglumine-enhanced liver MRI as the sole preoperative imaging technique: A prospective study of living liver donors. *AJR* 2006;187:1223-1233.
- 34.- Huppertz A, Balzer T, Blakeborough A et al. Improved detection of focal liver lesions at MR imaging: Multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. *Radiology* 2004;230:266-275
- 35.- Saito K, Kotake F, Ito N, et al. Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: Quantitative evaluation of tumor enhancement in hepatobiliary phase. *Magnetic Resonance in Medical Sciences* 2005;4:1-9
- 36.- Huppertz A, Haraida S, Kraus A, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: Correlation with histopathologic findings and spiral CT-initial observations. *Radiology* 2005;234:468-478.
- 37.- Halavaara J, Breuer J, Ayuso C, et al. Liver tumor characterization: comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT- A multicenter trial. *J Comput Assist Tomogr.* 2006; 30:345-354
- 38.- Hamm B, Staks Th, MuhlerA, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: Safety, pharmacokinetics, and MR imaging. *Radiology* 1995; 195; 785-792
- 39.- Vogl Th, Kummel S, Hammerstingl R. et al. Liver tumors. Comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. *Radiology* 1996; 200.59-67
- 40.-Marchal NY, Muhler YJ, Baert LG, et al. Prolonged positive contrast enhancement with Gd-EOB-DTPA in experimental liver tumors : potential value in tissue characterization. *J Magn Reson Imaging* 1994; 4:355-363
- 41.- Marchal NY. Enhanced magnetic resonante imaging for tissue characterization of liver abnormalities with hepatobiliary contrast agents: an overview of preclinical animal experiments. *Top Magn Reson Imaging* 1998; 9:183-195